Loading...
Long-term therapy with thiopurines for inflammatory bowel disease (IBD) is associated with a several-fold increased risk for non-Hodgkin lymphoma. However, data on whether tumor necrosis factor α (TNF-α) inhibitors administered alone increase lymphoma risk are mixed. In the current study, investigators conducted a retrospective database review to analyze the risks for T-cell non-Hodgkin lymphoma in patients receiving TNF-α inhibitors, thiopurines, or both.
Investigators identified 91 cases of T-cell non-Hodgkin lymphoma in patients treated with TNF-α inhibitors from the FDA Adverse Event Reporting System between 2003 and 2010 and 9 additional cases from the Medline database. Of these 100 patients, 38 had rheumatoid arthritis, 36 had Crohn di…